Literature DB >> 25370806

Measures of arthritis activity associated with patient-reported improvement in rheumatoid arthritis when assessed prospectively versus retrospectively.

Michael M Ward1, Lori C Guthrie1, Maria I Alba1.   

Abstract

OBJECTIVE: The patient global assessment (PGA) is intended to provide an integrated summary of all symptoms of arthritis, but it is not clear which disease features most impact patients' assessments of changes in their overall status. We investigated what aspects of rheumatoid arthritis (RA) activity correlated best with prospectively measured changes in the PGA and with patients' retrospective judgments of improvement.
METHODS: We studied 250 patients with active RA in a prospective longitudinal study. Disease activity measures were collected before and after treatment escalation. Prospectively measured changes in PGA and patients' judgments of improvement or worsening at the followup visit were tested for correlations with changes in patient-reported measures of symptoms and functioning, joint counts, and laboratory tests.
RESULTS: Patients improved during the study, with the mean ± SD PGA decreasing from 55.6 ± 25.2 to 37.6 ± 24.0. At the followup visit, 167 patients (66.8%) reported improvement in overall arthritis status. Changes in pain severity, stiffness severity, and fatigue were the only significant correlates of changes in PGA. In contrast, changes in the Health Assessment Questionnaire, tender joint count or Disease Activity Score in 28 joints (DAS28), and stiffness severity were associated with retrospective judgments of improvement.
CONCLUSION: Prospectively measured changes in PGA in RA were related solely to other patient-reported measures, but patients' retrospective judgments of improvement were related to functional limitations, tender joint count, and DAS28. Patients' subjective judgments of improvement reflect aspects of RA different from the PGA and may be a simple complementary measure of treatment efficacy. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25370806      PMCID: PMC4556344          DOI: 10.1002/acr.22509

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  15 in total

1.  Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis.

Authors:  Jennifer L Barton; John Imboden; Jonathan Graf; David Glidden; Edward H Yelin; Dean Schillinger
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

2.  Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?

Authors:  Nasim Ahmed Khan; Horace Jack Spencer; Essam Ahmed Abda; Rieke Alten; Christof Pohl; Codrina Ancuta; Massimiliano Cazzato; Pál Géher; Laure Gossec; Dan Henrohn; Merete Lund Hetland; Nevsun Inanc; Johannes Wg Jacobs; Eduardo Kerzberg; Maria Majdan; Omondi Oyoo; Ruben A Peredo-Wende; Zahraa Ibrahim Selim; Fotini Nikolaos Skopouli; Alberto Sulli; Kim Hørslev-Petersen; Peter C Taylor; Tuulikki Sokka
Journal:  Ann Rheum Dis       Date:  2012-04-24       Impact factor: 19.103

3.  Comment on the use of self-reporting instruments to assess patients with rheumatoid arthritis: the longitudinal association between the DAS28 and the VAS general health.

Authors:  W Kievit; P M J Welsing; E M M Adang; A M Eijsbouts; P F M Krabbe; P L C M van Riel
Journal:  Arthritis Rheum       Date:  2006-10-15

4.  Measurement of health status. Ascertaining the minimal clinically important difference.

Authors:  R Jaeschke; J Singer; G H Guyatt
Journal:  Control Clin Trials       Date:  1989-12

5.  "Arthritis specific" global health analog scales assess "generic" health related quality-of-life in patients with rheumatoid arthritis.

Authors:  J F Fries; D R Ramey
Journal:  J Rheumatol       Date:  1997-09       Impact factor: 4.666

6.  Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials.

Authors:  Michael M Ward; Lori C Guthrie; Maria I Alba
Journal:  Ann Rheum Dis       Date:  2014-05-01       Impact factor: 19.103

7.  Low back pain recollection versus concurrent accounts: outcomes analysis.

Authors:  Edgar G Dawson; Linda E A Kanim; Parveen Sra; Frederick J Dorey; Theodore B Goldstein; Rick B Delamarter; Harvinder S Sandhu
Journal:  Spine (Phila Pa 1976)       Date:  2002-05-01       Impact factor: 3.468

8.  The relative importance of pain and functional disability to patients with rheumatoid arthritis.

Authors:  M M Ward; J P Leigh
Journal:  J Rheumatol       Date:  1993-09       Impact factor: 4.666

9.  Comparison of physician and patient global assessments over time in patients with rheumatoid arthritis: a retrospective analysis from the RADIUS cohort.

Authors:  Joseph A Markenson; Andrew S Koenig; Jing Yuan Feng; Sandeep Chaudhari; Debra J Zack; David Collier; Arthur Weaver
Journal:  J Clin Rheumatol       Date:  2013-09       Impact factor: 3.517

10.  Sources of discrepancy in patient and physician global assessments of rheumatoid arthritis disease activity.

Authors:  Giuliana Nicolau; Melissa M Yogui; Tatiana L Vallochi; Reinaldo J Gianini; Ieda M M Laurindo; Gilberto S Novaes
Journal:  J Rheumatol       Date:  2004-07       Impact factor: 4.666

View more
  2 in total

1.  Fatigue, pain and patient global assessment responses to biological treatment are unpredictable, and poorly inter-connected in individual rheumatoid arthritis patients followed in the daily clinic.

Authors:  Ole Rintek Madsen; Eva Marie Egsmose
Journal:  Rheumatol Int       Date:  2016-07-23       Impact factor: 2.631

Review 2.  Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability.

Authors:  Etheresia Pretorius; Oore-Ofe Akeredolu; Prashilla Soma; Douglas B Kell
Journal:  Exp Biol Med (Maywood)       Date:  2016-11-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.